Hematology Frontier

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.

Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from myeloid stem cells, characterized by significant biological diversity and generally poor prognosis. The global disease burden of AML continues to rise, with the age-standardized incidence increasing by 87.3% between 1990 and 2021, underscoring the urgent need for improved therapeutic strategies.

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was held in Beijing, bringing together leading experts from China and abroad to discuss advances in thrombosis, hemostasis, hematologic malignancies, and immunology.

In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026), hosted by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and organized by the National Clinical Research Center for Hematologic Diseases and the Institute of Hematology at Peking University, will be grandly held in Beijing on April 24–25, 2026.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential academic events in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry leaders to explore cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while advancing academic exchange and innovation in the field.

Immune thrombocytopenia (ITP) is a complex autoimmune disorder involving multiple immune pathways and abnormalities in platelet production. In recent years, continuous advances in drug development and evolving treatment paradigms have been reshaping the clinical landscape of ITP.